The study explores the use of structurally reprogrammed modified citrus pectin (MCP) to enhance the sequestration of galectin-3, a protein linked to inflammation and tissue remodeling in osteoarthritis. By leveraging MCP’s properties, the research aims to improve therapeutic strategies for osteoarthritis immunotherapy. Additionally, the construction of an injectable carboxymethyl chitosan/berberine hydrogel is discussed. This hydrogel serves as a delivery system for MCP, potentially increasing its bioavailability and therapeutic efficacy. The combination of MCP with the hydrogel formulation offers a novel approach to target galectin-3, thereby modulating the inflammatory response and promoting tissue repair in osteoarthritis patients. This multifaceted strategy may pave the way for innovative treatments that address both symptom relief and underlying disease mechanisms, positioning MCP and the hydrogel as promising candidates in osteoarthritis research and therapeutic development. Enhanced understanding of these interactions could lead to better management strategies for this prevalent joint disorder.
Source link
